Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sukaina Virji

Sukaina has been reporting on all aspects of the pharmaceutical and biotechnology space since 2000. In her role as News Editor, she is tasked with ensuring Scrip Intelligence continues to provide the business critical information that its subscribers rely on. Sukaina's prior positions include Editor of the newsletter BioVenture View and the magazine BioPeople. She has a PhD in biochemistry and molecular biology from University College London. Based in the UK, Sukaina is often asked to appear on TV and radio to commentate on business and R&D strategy related to the industry.
Advertisement
Set Alert for Articles By Sukaina Virji

Latest From Sukaina Virji

Misery In Myelofibrosis: Pacritinib Setback A Boost For Jakafi

With the commercial opportunity in the myelofibrosis market expected to double to over $1bn in the next five years, competition to Incyte/Novartis's Jakafi seems further away than ever as CTI BioPharma pulls the European regulatory filing for pacritinib.

Research & Development Regulation

Ultragenyx Seizure Miss Is Not A Catastrophe, Claim Analysts And Management

Analysts claim Ultragenyx's Phase II failure of triheptanoin for seizures in patients with the rare GLUT1-deficiency syndrome (GLUT1-DS) doesn't mean the end of the road for the product, and still see plenty of potential commercial success down the road for the company. However, the company's share price slipped up to 15% on the news.

Research & Development Metabolic Disorders

Heartache For Novartis As Serelaxin Failure Ups Pressure On Entresto

Novartis's latest Phase III study of serelaxin has failed, deleting a significant chunk of forecasted revenue that analysts had attributed to the heart failure drug candidate.

Research & Development Clinical Trials

As MS Space Awaits Ocrevus, MedDay Sees 'Synergistic' Positioning Opportunity

With Roche's Ocrevus expected to be given the green light at any moment for the underserved progressive multiple sclerosis market, a tiny French biotech with a "synergistic" product for the same indication also believes it could soon have a commercial success on its hands.

Commercial Neurology

Inhaled Anti-Infectives With Extended Lung Retention: Pulmocide Secures Cash To Fund Trials

When tackling pulmonary infections, getting therapeutics into the lungs that stay there long enough to be effective is the key challenge. Pulmocide has just persuaded investors it is up to the task, raising $30m to fund two clinical programs.

Commercial Companies

Sanofi's New Gaucher Drug Cost Doesn't Add Up For NICE

Sanofi and UK HTA body NICE have come up with drastically different numbers for how much new oral Gaucher disease treatment Cerdelga will end up costing per patient. The result? Despite being the first oral treatment option for patients, NICE doesn't think Cerdelga is worth it.

Reimbursement Rare Diseases
See All
Advertisement
UsernamePublicRestriction

Register